The American Lung Association condemned the recently announced acquisition of Vectura by cigarette maker Philip Morris (NYSE:PM).
Earlier this month, Philip Morris announced that it agreed to acquire inhaled drug delivery technology developer Vectura for $1.2 billion.
In response to the acquisition, American Lung Association president & CEO Harold Wimmer and American Thoracic Society president Dr. Lynn Schnapp released a joint statement calling the purchase “the latest reprehensible choice from a company that has profited from addicting users to its deadly products.”
Get the full story at our sister site, Drug Delivery Business News.